The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
The Molecular Pathogenesis of Osteosarcoma: A Review
Open accessAbstract
Osteosarcoma is the most common primary malignancy of bone. It arises in bone during periods of rapid growth and primarily affects adolescents and young adults. The 5-year survival rate for osteosarcoma is 60%–70%, with no significant improvements in prognosis since the advent of multiagent chemotherapy. Diagnosis, staging, and surgical management of osteosarcoma remain focused on our anatomical understanding of the disease. As our knowledge of the molecular pathogenesis of osteosarcoma expands, potential therapeutic targets are being identified. A comprehensive understanding of these mechanisms is essential if we are to improve the prognosis of patients with osteosarcoma through tumour-targeted therapies. This paper will outline the pathogenic mechanisms of osteosarcoma oncogenesis and progression and will discuss some of the more frontline translational studies performed to date in search of novel, safer, and more targeted drugs for disease management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tensional homeostasis and the malignant phenotype
Paszek, M. J., Zahir, N., Johnson, K. R., Lakins, J. N., Rozenberg, G. I., Gefen, A., Reinhart-King, C. A., Margulies, S. S., Dembo, M., Boettiger, D., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.010 · Cited by 3,941
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699
Cell Movement Is Guided by the Rigidity of the Substrate
Lo, C.-M., Wang, H.-B., Dembo, M., & Wang, Y.-L. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76279-5 · Cited by 3,289
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Matrix Metalloproteinases: A Review
Birkedal-Hansen, H., Moore, W. G. I., Bodden, M. K., Windsor, L. J., Birkedal-Hansen, B., DeCarlo, A., & Engler, J. A. (1993) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/10454411930040020401 · Cited by 2,970
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393 · cited 1×
“Despite modern treatment protocols that combine chemotherapy, surgery, and sometimes radiotherapy, the 5year survival rate for patients diagnosed with osteosarcoma remains at 60%–70% [1].”
BackgroundCampbell's Operative Orthopaedics
(1956) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1956.tb57228.x · Cited by 2,158
The Epidemiology of Osteosarcoma
Ottaviani, G., & Jaffe, N. (2009) · Cancer Treatment and Research · doi:10.1007/978-1-4419-0284-9_1 · Cited by 1,786
VEGF as a Key Mediator of Angiogenesis in Cancer
Carmeliet, P. (2005) · Oncology · doi:10.1159/000088478 · Cited by 1,768
Structural Basis of Integrin Regulation and Signaling
Luo, B.-H., Carman, C. V., & Springer, T. A. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141618 · Cited by 1,660
The protein kinase B/Akt signalling pathway in human malignancy
Nicholson, K. M., & Anderson, N. G. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(01)00271-6 · Cited by 1,639
Regulation of matrix metalloproteinases: An overview
Chakraborti, S., Mandal, M., Das, S., Mandal, A., & Chakraborti, T. (2003) · Molecular and Cellular Biochemistry · doi:10.1023/a:1026028303196 · Cited by 1,128
Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis
Shibuya, M., & Claesson-Welsh, L. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.012 · Cited by 1,062
Berrier, A. L., & Yamada, K. M. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21237 · Cited by 957
Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting
Lobov, I. B., Renard, R. A., Papadopoulos, N., Gale, N. W., Thurston, G., Yancopoulos, G. D., & Wiegand, S. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611206104 · Cited by 774
Oh, J., Takahashi, R., Kondo, S., Mizoguchi, A., Adachi, E., Sasahara, R. M., Nishimura, S., Imamura, Y., Kitayama, H., Alexander, D. B., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00597-9 · Cited by 728
Hypoxia: A key regulator of angiogenesis in cancer
Liao, D., & Johnson, R. S. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9066-y · Cited by 721
The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis
Khanna, C., Wan, X., Bose, S., Cassaday, R., Olomu, O., Mendoza, A., Yeung, C., Gorlick, R., Hewitt, S. M., & Helman, L. J. (2004) · Nature Medicine · doi:10.1038/nm982 · Cited by 705
Biology and Therapeutic Advances for Pediatric Osteosarcoma
Marina, N., Gebhardt, M., Teot, L., & Gorlick, R. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-422 · Cited by 671
The CCN Family of Angiogenic Regulators: The Integrin Connection
Lau, L. F., & Lam, S. C.-T. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4456 · Cited by 648
Redox-dependent downregulation of Rho by Rac
Nimnual, A. S., Taylor, L. J., & Bar-Sagi, D. (2003) · Nature Cell Biology · doi:10.1038/ncb938 · Cited by 515
Osteosarcoma (Osteogenic sarcoma)
Picci, P. (2007) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-2-6 · Cited by 505
VEGF-A and the Induction of Pathological Angiogenesis
Nagy, J. A., Dvorak, A. M., & Dvorak, H. F. (2007) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.2.010506.134925 · Cited by 474
The role of NFAT in osteoclast formation
TAKAYANAGI, H. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.071 · Cited by 442
Molecular Biology of Bone Metastasis
Kingsley, L. A., Fournier, P. G. J., Chirgwin, J. M., & Guise, T. A. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0234 · Cited by 435
German, J. (1995) · Dermatologic Clinics · doi:10.1016/s0733-8635(18)30101-3 · Cited by 422
Mutator phenotype of Werner syndrome is characterized by extensive deletions.
Fukuchi, K., Martin, G. M., & Monnat, R. J. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.15.5893 · Cited by 419
M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase
Glantschnig, H., Fisher, J. E., Wesolowski, G., Rodan, G. A., & Reszka, A. A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401285 · Cited by 350
Tran, J., Rak, J., Sheehan, C., Saibil, S. D., LaCasse, E., Korneluk, R. G., & Kerbel, R. S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1589 · Cited by 333
Tanaka, S., Nakamura, K., Takahasi, N., & Suda, T. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00327.x · Cited by 320
Osteosarcoma treatment: state of the art
Ta, H. T., Dass, C. R., Choong, P. F. M., & Dunstan, D. E. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9186-7 · Cited by 314
Self-citation(2000) · PubMed · Cited by 304
New Roles for Src Kinases in Control of Cell Survival and Angiogenesis
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)80664-9 · Cited by 300
DVORAK, H. F. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01361.x · Cited by 296
c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption
Tanaka, S., Amling, M., Neff, L., Peyman, A., Uhlmann, E., Levy, J. B., & Baron, R. (1996) · Nature · doi:10.1038/383528a0 · Cited by 288
Transforming Growth Factor β Affects Osteoclast Differentiation via Direct and Indirect Actions
Quinn, J. M. W., Itoh, K., Udagawa, N., Häusler, K., Yasuda, H., Shima, N., Mizuno, A., Higashio, K., Takahashi, N., Suda, T., et al. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.10.1787 · Cited by 278
Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome
Teodoro, J. G., Evans, S. K., & Green, M. R. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0221-2 · Cited by 260
Mutation spectrum of the retinoblastoma gene in osteosarcomas.
Wadayama, B., Toguchida, J., Shimizu, T., Ishizaki, K., Sasaki, M. S., Kotoura, Y., & Yamamuro, T. (1994) · PubMed · Cited by 250
Ezrin, a key component in tumor metastasis
Hunter, K. W. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.03.001 · Cited by 229
Regulation of tumor angiogenesis by thrombospondin-1
Ren, B., Yee, K. O., Lawler, J., & Khosravi-Far, R. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.11.002 · Cited by 225
Troponin I is present in human cartilage and inhibits angiogenesis
Moses, M. A., Wiederschain, D., Wu, I., Fernandez, C. A., Ghazizadeh, V., Lane, W. S., Flynn, E., Sytkowski, A., Tao, T., & Langer, R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.2645 · Cited by 219
López-Ríos, F., Illei, P. B., Rusch, V., & Ladanyi, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17102-x · Cited by 208
Urokinase Plasminogen Activator System: A Multifunctional Role in Tumor Progression and Metastasis
Choong, P., & Nadesapillai, A. P. W. (2003) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo0000093845.72468.bd · Cited by 208
Self-citationA Cathepsin K Inhibitor Reduces Breast Cancer–Induced Osteolysis and Skeletal Tumor Burden
Le Gall, C., Bellahcène, A., Bonnelye, E., Gasser, J. A., Castronovo, V., Green, J., Zimmermann, J., & Clézardin, P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3940 · Cited by 204
Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma.
McIntyre, J. F., Smith-Sorensen, B., Friend, S. H., Kassell, J., Borresen, A. L., Yan, Y. X., Russo, C., Sato, J., Barbier, N., & Miser, J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.5.925 · Cited by 200
Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma.
Feugeas, O., Guriec, N., Babin-Boilletot, A., Marcellin, L., Simon, P., Babin, S., Thyss, A., Hofman, P., Terrier, P., Kalifa, C., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.467 · Cited by 199
Ley, R., Ewings, K. E., Hadfield, K., Howes, E., Balmanno, K., & Cook, S. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311578200 · Cited by 194
Nishida, T., Nakanishi, T., Asano, M., Shimo, T., & Takigawa, M. (2000) · Journal of Cellular Physiology · doi:10.1002/1097-4652(200008)184:2<197::aid-jcp7>3.0.co;2-r · Cited by 190
Alterations of thep53, Rb andMDM2 genes in osteosarcoms
Miller, C. W., Aslo, A., Won, A., Tan, M., Lampkin, B., & Koefflar, H. P. (1996) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01213553 · Cited by 190
Masson, V., De La Ballina, L. R., Munaut, C., Wielockx, B., Jost, M., Maillard, C., Blacher, S., Bajou, K., Itoh, T., Itohara, S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2140fje · Cited by 183
Lamoureux, F., Richard, P., Wittrant, Y., Battaglia, S., Pilet, P., Trichet, V., Blanchard, F., Gouin, F., Pitard, B., Heymann, D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4130 · Cited by 181
C-myc and c-fos in Human Osteosarcoma: Prognostic Value of mRNA and Protein Expression
Gamberi, G., Benassi, M. S., Bohling, T., Ragazzini, P., Molendini, L., Sollazzo, M. R., Pompetti, F., Merli, M., Magagnoli, G., Balladelli, A., et al. (1998) · Oncology · doi:10.1159/000011912 · Cited by 179
Cathepsin K Inhibitors: A Novel Target for Osteoporosis Therapy
Stoch, S., & Wagner, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100450 · Cited by 178
Clark, J. C. M., Thomas, D. M., Choong, P. F. M., & Dass, C. R. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9093-8 · Cited by 176
Self-citationUrokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
Choong, P., & Nadesapillai, A. P. W. (2003) · PubMed · doi:10.1097/01.blo.0000093845.72468.bd · Cited by 167
Self-citationJan, Y., Matter, M., Pai, J.-T., Chen, Y.-L., Pilch, J., Komatsu, M., Ong, E., Fukuda, M., & Ruoslahti, E. (2004) · Cell · doi:10.1016/s0092-8674(04)00204-1 · Cited by 165
Shimizu, T., Ishikawa, T., Sugihara, E., Kuninaka, S., Miyamoto, T. K., Mabuchi, Y., Matsuzaki, Y., Tsunoda, T., Miya, F., Morioka, H., et al. (2010) · Oncogene · doi:10.1038/onc.2010.312 · Cited by 159
Inactivation of p53 gene in human and murine osteosarcoma cells
Chandar, N., Billig, B., McMaster, J. H., & Novak, J. F. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.43 · Cited by 157
p53 and MDM2 alterations in osteosarcomas
Lonardo, F., Ueda, T., Huvos, A. G., Healey, J. H., & Ladanyi, M. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970415)79:8<1541::aid-cncr15>3.0.co;2-y · Cited by 147
Bloom's syndrome. III. Analysis of the chromosome aberration characteristic of this disorder
GERMAN, J. L., Crippa, L., & Bloom, D. (1974) · Chromosoma · doi:10.1007/bf00290993 · Cited by 146
The insulin‐like growth factor system and sarcomas
Rikhof, B., de Jong, S., Suurmeijer, A. J. H., Meijer, C., & van der Graaf, W. T. A. (2008) · The Journal of Pathology · doi:10.1002/path.2499 · Cited by 145
Wang, Z., Liang, J., Schellander, K., Wagner, E. F., & Grigoriadis, A. E. (1995) · PubMed · Cited by 140
Akiyama, T., Dass, C. R., & Choong, P. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0530 · Cited by 139
Self-citationTransforming Growth Factor-Beta in Osteolytic Breast Cancer Bone Metastases
Guise, T. A., & Chirgwin, J. M. (2003) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000093055.96273.69 · Cited by 136
Blockade of the RhoA-JNK-c-Jun-MMP2 Cascade by Atorvastatin Reduces Osteosarcoma Cell Invasion
Fromigué, O., Hamidouche, Z., & Marie, P. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801436200 · Cited by 136
Matsumoto, T., & Mugishima, H. (2006) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.13.130 · Cited by 131
Stature of young people with malignant bone tumors
Cotterill, S. J., Wright, C. M., Pearce, M. S., & Craft, A. W. (2003) · Pediatric Blood & Cancer · doi:10.1002/pbc.10437 · Cited by 129
Alteration of pRb/p16/cdk4 regulation in human osteosarcoma
Benassi, M. S., Molendini, L., Gamberi, G., Ragazzini, P., Sollazzo, M. R., Merli, M., Asp, J., Magagnoli, G., Balladelli, A., Bertoni, F., et al. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991022)84:5<489::aid-ijc7>3.0.co;2-d · Cited by 115
Genomic Alterations and Allelic Imbalances Are Strong Prognostic Predictors in Osteosarcoma
Smida, J., Baumhoer, D., Rosemann, M., Walch, A. K., Bielack, S., Poremba, C., REMBERGER, K., Korsching, E., Scheurlen, W. G., Dierkes, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0284 · Cited by 115
Franchi, A., Arganini, L., Baroni, G., Calzolari, A., Capanna, R., Campanacci, D. A., Caldora, P., Masi, L., Brandi, M. L., & Zampi, G. (1998) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199807)185:3<284::aid-path94>3.0.co;2-z · Cited by 112
The urokinase plasminogen activator receptor as a gene therapy target for cancer
Pillay, V., Dass, C. R., & Choong, P. (2006) · Trends in biotechnology · doi:10.1016/j.tibtech.2006.10.011 · Cited by 109
Self-citationEvidence against a Role for SV40 in Human Mesothelioma
Manfredi, J. J., Dong, J., Liu, W.-J., Resnick‐Silverman, L., Qiao, R., Chahinian, P. A., Šarić, M., Gibbs, A. R., Phillips, J. I., Murray, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2461 · Cited by 108
The role of the matrix metalloproteinases during in vitro vessel formation
Burbridge, M. F., Cogé, F., Galizzi, J., Boutin, J. A., West, D. C., & Tucker, G. C. (2002) · Angiogenesis · doi:10.1023/a:1023889805133 · Cited by 107
Switch from αvβ5 to αvβ6 integrin expression protects squamous cell carcinomas from anoikis
Janes, S. M., & Watt, F. M. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200312074 · Cited by 106
Osteosarcoma – conventional treatment vs. gene therapy
Tan, M. L., Choong, P., & Dass, C. R. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.2.7385 · Cited by 99
Self-citationHauben, E. I., Arends, J., Vandenbroucke, J. P., van Asperen, C. J., Marck, E. V., & Hogendoorn, P. C. W. (2003) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201012 · Cited by 94
Height as a Risk Factor for Osteosarcoma
Longhi, A., Pasini, A., Cicognani, A., Baronio, F., Pellacani, A. U. E., Baldini, N., & Bacci, G. (2005) · Journal of Pediatric Hematology/Oncology · doi:10.1097/01.mph.0000169251.57611.8e · Cited by 92
Growth and development and other risk factors for osteosarcoma in children and young adults
Gelberg, K. H., Fitzgerald, E., Hwang, S. E., & Dubrow, R. (1997) · International Journal of Epidemiology · doi:10.1093/ije/26.2.272 · Cited by 89
Rac1 Protects Epithelial Cells against Anoikis
Coniglio, S. J., Jou, T., & Symons, M. H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102299200 · Cited by 88
Ek, E. T., Dass, C. R., Contreras, K. G., & Choong, P. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701044 · Cited by 87
Self-citationDecreased Pigment Epithelium–Derived Factor Expression in Human Breast Cancer Progression
Cai, J., Parr, C., Watkins, G., Jiang, W. G., & Boulton, M. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0094 · Cited by 86
Kolb, E. A., Kamara, D., Zhang, W., Lin, J., Hingorani, P., Baker, L. H., Houghton, P. J., & Gorlick, R. G. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22479 · Cited by 83
Inhibition of Protein Kinase c-Src as a Therapeutic Approach for Cancer and Bone Metastases
Rucci, N., Susa, M., & Teti, A. M. (2008) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152008783961905 · Cited by 80
Prognostic Relevance of Increased Angiogenesis in Osteosarcoma
Kreuter, M., Bieker, R., Bielack, S., Auras, T., Buerger, H., Gosheger, G., Jürgens, H., Berdel, W. E., & Mesters, R. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0969 · Cited by 78
Ek, E. T., Dass, C. R., Contreras, K. G., & Choong, P. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9062-1 · Cited by 75
Self-citationFranchi, A., Calzolari, A., & Zampi, G. (1998) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280050199 · Cited by 75
Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis
Hofbauer, L. C., & Heufelder, A. E. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1390152 · Cited by 74
Dong, J., Demarest, S. J., Sereno, A., Tamraz, S., Langley, E. J., Doern, A., Snipas, T., Perron, K., Joseph, I. B. J., Glaser, S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1018 · Cited by 69
Husmann, K., Muff, R., Bolander, M. E., Sarkar, G., Born, W., & Fuchs, B. (2007) · Molecular Carcinogenesis · doi:10.1002/mc.20362 · Cited by 68
Prognostic Value of CCN3 in Osteosarcoma
Perbal, B., Zuntini, M., Zambelli, D., Serra, M., Sciandra, M., Cantiani, L., Lucarelli, E., Picci, P., & Scotlandi, K. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0806 · Cited by 67
Ek, E. T., Dass, C. R., Contreras, K. G., et al. (2007) · Journal of Orthopaedic Research® · doi:10.1002/jor.20434 · Cited by 63
Self-citationUrokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas
Choong, P., Fernö, M., Åkerman, M., Willén, H., Långström, E., Gustaeson, P., Alvegård, T. A., & Rydholm, A. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960822)69:4<268::aid-ijc5>3.0.co;2-v · Cited by 60
Self-citationYang, R., Hoang, B. H., Kubo, T., Kawano, H., Chou, A. J., Sowers, R. S., Huvos, A. G., Meyers, P. A., Healey, J. H., & Gorlick, R. G. (2007) · International Journal of Cancer · doi:10.1002/ijc.22749 · Cited by 56
Kang, H.-G., Kim, H., Kim, K., Oh, J. H., Lee, M., Seol, S. M., & Han, I. (2007) · Journal of Orthopaedic Research® · doi:10.1002/jor.20323 · Cited by 56
Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma
Dass, C. R., Nadesapillai, A. P. W., Robin, D., Howard, M. L., Fisher, J., Zhou, H., & Choong, P. (2005) · Clinical & Experimental Metastasis · doi:10.1007/s10585-006-9004-3 · Cited by 55
Self-citationLeaner, V. D., Chick, J. F. B., Donninger, H., Linniola, I., Mendoza, A., Khanna, C., & Birrer, M. J. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2009.071006 · Cited by 50
Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma
Park, H., Jung, W. W., Bertoni, F., Bacchini, P., Park, J. H., Kim, Y.-W., & Park, Y.-K. (2004) · Pathology - Research and Practice · doi:10.1016/j.prp.2004.04.006 · Cited by 48
Ganjavi, H., Gee, M. F. W., Narendran, A., Parkinson, N., Krishnamoorthy, M., Freedman, M. H., & Malkin, D. M. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700909 · Cited by 47
Skeletal metastases: Decreasing tumor burden by targeting the bone microenvironment
Chirgwin, J. M., & Guise, T. A. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21556 · Cited by 42
Cancer cell apoptotic pathways mediated by PEDF: prospects for therapy
Broadhead, M. L., Dass, C. R., & Choong, P. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.08.003 · Cited by 41
Self-citationOsteoclast Differentiation Factor in Human Osteosarcoma Cell Line
Kinpara, K., Mogi, M., Kuzushima, M., & Togari, A. (2000) · Journal of Immunoassay · doi:10.1080/01971520009349540 · Cited by 39
Association between TGFBR1*6A and osteosarcoma: A Chinese case-control study
Hu, Y.-S., Pan, Y., Li, W., Zhang, Y., Li, J., & Ma, B. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-169 · Cited by 38
Heinsohn, S., Evermann, U., Stadt, U. Z., Bielack, S., & Kabisch, H. (2007) · International Journal of Oncology · doi:10.3892/ijo.30.5.1205 · Cited by 35
The expression and significance of IDH1 and p53 in osteosarcoma
Hu, X., Yu, A., Qi, B., Fu, T., Wu, G., Zhou, M., Luo, J., & Xu, J.-H. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-43 · Cited by 35
Regulation of Matrix Metalloproteinases
Saja, K. (2006) · Shodhganga · Cited by 34
Wang, Y., Xiong, J., Wang, S., Yu, Y., Wang, B., Chen, Y., Shi, H.-F., & Qiu, Y. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0453-2 · Cited by 33
Gagiannis, S., Müller, M., Uhlemann, S., Koch, A., Melino, G., Krammer, P. H., Nawroth, P. P., Brune, M., & Schilling, T. (2009) · International Journal of Cancer · doi:10.1002/ijc.24471 · Cited by 32
Berdiaki, A., Datsis, G. A., Nikitovic, D., Tsatsakis, A. M., Katonis, P., Karamanos, N. K., & Tzanakakis, G. N. (2010) · IUBMB Life · doi:10.1002/iub.320 · Cited by 31
Molecular Biology and Therapeutics in Musculoskeletal Oncology*
Guise, T. A., O’Keefe, R. J., Randall, R. L., & Terek, R. M. (2009) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.i.00012 · Cited by 27
Tan, M. L., Choong, P., & Dass, C. R. (2010) · Cancer Cell International · doi:10.1186/1475-2867-10-9 · Cited by 26
Self-citationEngels, E. A. (2005) · Expert Review of Vaccines · doi:10.1586/14760584.4.2.197 · Cited by 25
Prognostic relevance of increased angiogenesis in osteosarcoma
Kreuter, M., Bieker, R., Bielack, S., Auras, T., Buerger, H., Gosheger, G., Jürgens, H., Berdel, W. E., & Mesters, R. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.9022 · Cited by 22
Radiation-Induced Osteosarcoma Arising 20 years after the Treatment of Ewing's Sarcoma
Longhi, A., Barbieri, E., Fabbri, N., Macchiagodena, M., Favale, L., Lippo, C., Salducca, N., & Bacci, G. (2003) · Tumori Journal · doi:10.1177/030089160308900526 · Cited by 21
Arvanitis, C., Bendapudi, P. K., Tseng, J. R., Gambhir, S. S., & Felsher, D. W. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.12.6947 · Cited by 14
Navid, F., Letterio, J. J., Yeung, C. L., Pegtel, D. M., & Helman, L. J. (2000) · Sarcoma · doi:10.1080/13577140020008057 · Cited by 13
Cited by
A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion
Pierron, G., Tirode, F., Lucchesi, C., Reynaud, S., Ballet, S., Cohen-Gogo, S., Perrin, V., Coindre, J.-M., & Delattre, O. (2012) · Nature Genetics · doi:10.1038/ng.1107 · Cited by 478
Bone Microenvironment and Osteosarcoma Metastasis
Yang, C., Tian, Y., Zhao, F., Chen, Z., Su, P., Li, Y., & Qian, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21196985 · Cited by 291
Koirala, P., Roth, M. E., Gill, J., Piperdi, S., Chinai, J. M., Geller, D. S., Hoang, B. H., Park, A., Fremed, M. A., Zang, X., et al. (2016) · Scientific Reports · doi:10.1038/srep30093 · Cited by 267
New molecular insights into osteosarcoma targeted therapy
Yang, J., & Zhang, W. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283622c1b · Cited by 262
Koirala, P., Roth, M. E., Gill, J., Chinai, J. M., Ewart, M. R., Piperdi, S., Geller, D. S., Hoang, B. H., Fatakhova, Y. V., Ghorpade, M., et al. (2016) · Scientific Reports · doi:10.1038/srep31154 · Cited by 100
Metadata
- Authors
- Broadhead, M. L., Clark, J. C. M., Myers, D. E., Dass, C. R., & Choong, P. F. M.
- Venue
- Sarcoma
- Publisher
- Hindawi Limited
- Published
- 2011
- Volume
- 2011
- Pages
- 1-12
- ISSN
- 1357-714X (ISSN-L)
- 1369-1643
- OpenAlex
- W2068477388
- Cited by
- 346
- References
- 116
- FWCI
- 17.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.